Navigation Links
First Baby With Artificial Heart in Japan
Date:8/6/2012

BERLIN, August 6, 2012 /PRNewswire/ --

- Cross reference: Picture is available at epa european pressphoto agency (http://www.epa.eu) and http://www.presseportal.de/pm/63857 -

For the first time in the history of Japan it was possible for doctors at the University of Tokyo, on August 2, 2012, to save a small child who was seriously suffering from a severe heart condition, aided by a Berlin Heart EXCOR® ventricular assist device. From a medical point of view the 14-month-old girl would only have been able to survive a few more weeks without the ventricular assist device. Now the artificial heart has taken over the pumping function of the completely weakened heart. Until a donor heart is found for the girl, weighing only seven kilograms, her life depends on the mechanical artificial heart.

The little patient would very probably not have survived waiting for transplantation in Japan, or for transport to another country for transplantation without the mechanical support. Assisted by the EXCOR® VAD, the infant could be stabilized well enough to be able to wait for transplantation.

The ventricular assist device EXCOR® from the German company Berlin Heart has been successfully employed in more than 1,100 children worldwide since its first implantation in 1990. It is the only system which can support all patients from newborns up to young people and adults such that they can survive until the heart transplantation. The EXCOR® VAD is used in 138 centers in 34 countries for bridging the often long waiting periods - in Europe 57.5% of the patients wait longer than one year for a new heart. Occasionally the heart can also recover so well, due to the mechanical support, that the assist device can be explanted and the patient can continue to live with their own heart.

The implantation was performed by Professor Ono and Professor Mu
'/>"/>

SOURCE Berlin Heart GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
8. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
9. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
10. Amgen Announces 2012 First Quarter Dividend
11. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Cleveleys (UK) (PRWEB) March 05, 2015 ... implantable polymer have received the CE mark (European) approval. ... the European Free Trade Association (EFTA) and the European ... mark has now been granted to implants supplied by ... disc spinal conditions. , Osimplant's Cervical Expandable Bladed ...
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
(Date:3/4/2015)... 04, 2015 USDM Life Sciences ... life sciences industry, hired David Blewitt as ... Cloud Compliance Services and Solutions at USDM Life Sciences ... applications while maintaining compliance with government regulations worldwide. ... an accomplished life sciences regulatory and IS compliance professional ...
(Date:3/4/2015)... , March 4, 2015 /CNW/ - Resverlogix Corp. ... has completed a collaborative research program with ...  Using Fast Collective Evolution Technology (FACET), Emerald ... all measurements obtained from each of 798 ... 2 clinical trials ASSERT, SUSTAIN and ASSURE. ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... Md., Dec. 5 Micromet, Inc. (Nasdaq:,MITI), a ... antibody-based products for cancer, inflammation and autoimmune,diseases, today ... Officer of Micromet, will be part of a ... Therapies For Cancer" at the 2007,RBC Capital Markets ...
... $8.1 Million Financing in Connection ... Reverse Stock Split Planned for January 2008, ... today announced that the Company has:, - Signed an agreement ... based in Israel. The acquisition,is expected to close tomorrow. The initial ...
... (AMEX: IMM ) announced today that the ... SA (Euronext Paris - ticker code BIO) to,commercialize ... the treatment of pneumocystis pneumonia (PCP) in AIDS ... also known as,African sleeping sickness. Pafuramidine is currently ...
Cached Biology Technology:Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007 2Amarin Signs Agreement to Acquire Ester Neurosciences 2Amarin Signs Agreement to Acquire Ester Neurosciences 3Amarin Signs Agreement to Acquire Ester Neurosciences 4Amarin Signs Agreement to Acquire Ester Neurosciences 5Amarin Signs Agreement to Acquire Ester Neurosciences 6Amarin Signs Agreement to Acquire Ester Neurosciences 7Amarin Signs Agreement to Acquire Ester Neurosciences 8Amarin Signs Agreement to Acquire Ester Neurosciences 9Amarin Signs Agreement to Acquire Ester Neurosciences 10Amarin Signs Agreement to Acquire Ester Neurosciences 11Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 2Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 3Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine 4
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... of the European corn borer has saved Midwest farmers billions ... in Science . Research conducted by several Midwest ... billion for corn growers in Illinois, Minnesota, and Wisconsin over ... this total benefiting non-Bt corn growers. Comparable estimates for Iowa ...
... Conn.A team of Yale University scientists has engineered the ... into incorporating foreign small molecules and embedding them within ... the journal ACS Chemical Biology this week, ... wall of a pathogenic "Gram-positive" bacteriaorganisms responsible not only ...
... States seeks to lessen its reliance on foreign oil, ... the National Renewable Energy Laboratory, a branch of the ... and could someday supply 3 percent to 5 percent ... to achieving that goal is figuring how to efficiently ...
Cached Biology News:Transgenic corn suppresses European corn borer, saves farmers billions 2Scientists trick bacteria with small molecules 2Brown University chemists simplify biodiesel conversion 2Brown University chemists simplify biodiesel conversion 3
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... samples, featuring 24-position turntable. Provides up to 30 minutes of walkaway time. Automatic Calibration. ... record keeping. RS-232 port. ... ... ...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
Biology Products: